1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Tinea Pedis (Athlete Foot) - Drugs In Development, 2022, provides an overview of the Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Athlete's foot, also known as tinea pedis, is a common foot infection caused by fungi called dermatophytes. Symptoms include dry flaking skin on the soles of the feet, unpleasant foot odour and small itchy bubbles or blisters on the soles of the feet. Treatment includes antifungal medicines.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Tinea Pedis (Athlete Foot) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Tinea Pedis (Athlete Foot) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tinea Pedis (Athlete Foot) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II and Phase 0 stages are 4 and 1 respectively.
Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Tinea Pedis (Athlete Foot) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tinea Pedis (Athlete Foot) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tinea Pedis (Athlete Foot) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tinea Pedis (Athlete Foot) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tinea Pedis (Athlete Foot) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tinea Pedis (Athlete Foot) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tinea Pedis (Athlete Foot) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Tinea Pedis (Athlete Foot) - Overview
- Tinea Pedis (Athlete Foot) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Tinea Pedis (Athlete Foot) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Tinea Pedis (Athlete Foot) - Companies Involved in Therapeutics Development
- Blueberry Therapeutics Ltd
- DermBiont Inc
- SaNOtize Research and Development Corp
- Taro Pharmaceuticals USA Inc
- Tinea Pedis (Athlete Foot) - Drug Profiles
- DBI-001 - Drug Profile
- Product Description
- Mechanism Of Action
- DBI-002 - Drug Profile
- Product Description
- Mechanism Of Action
- NORS-6491 - Drug Profile
- Product Description
- Mechanism Of Action
- TA-103 - Drug Profile
- Product Description
- Mechanism Of Action
- terbinafine hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- Tinea Pedis (Athlete Foot) - Dormant Projects
- Tinea Pedis (Athlete Foot) - Product Development Milestones
- Featured News & Press Releases
- Oct 22, 2019: DermBiont announces positive data from phase 2a clinical trial and start of phase 2b clinical trial for Athlete’s Foot with a topical live biotherapeutic
- Mar 13, 2019: DermBiont begins Phase 2 clinical trial for athlete's foot with a live bacterial topical probiotic
- Nov 23, 2018: Blueberry reports positive results from Phase I/II BB2603 trial
- Apr 26, 2017: Blueberry Therapeutics commence Phase I/II clinical trial of lead product BB2603
- Apr 04, 2017: Mike Davies presents at the "Adaptive Designs in Clinical Trials" conference
- Feb 28, 2017: Blueberry Therapeutics gains final approval for its first clinical trial
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Tinea Pedis (Athlete Foot), 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Tinea Pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd, 2022
- Tinea Pedis (Athlete Foot) - Pipeline by DermBiont Inc, 2022
- Tinea Pedis (Athlete Foot) - Pipeline by SaNOtize Research and Development Corp, 2022
- Tinea Pedis (Athlete Foot) - Pipeline by Taro Pharmaceuticals USA Inc, 2022
- Tinea Pedis (Athlete Foot) - Dormant Projects, 2022
- Number of Products under Development for Tinea Pedis (Athlete Foot), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Blueberry Therapeutics Ltd
- DermBiont Inc
- SaNOtize Research and Development Corp
- Taro Pharmaceuticals USA Inc
